Daré Bioscience, Inc.(DARE)Earnings, Financials & Key RatiosDaré Bioscience, Inc. (DARE) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q1
Negative: The company's deteriorating equity position of $734.5K and persistent quarterly operating losses suggest that the current capital structure is insufficient to support long-term clinical development without further dilutive financing.
Daré Bioscience, Inc. (DARE) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Recent stock market news and headlines for Daré Bioscience, Inc. (DARE)
Commercial Launch Begins Company's First Consumer Revenue Stream, Bringing Science-Backed Women's Health Solutions Directly to Consumers Commercial Launch Begins Company's First Consumer Revenue Stream, Bringing Science-Backed Women's Health Solutions Directly to Consumers
First consumer health product positions Daré for revenue generation while expanding its women's health leadership platform
President and CEO, Sabrina Martucci Johnson, to participate in featured industry panels and present Company's vision for transforming women's health President and CEO, Sabrina Martucci Johnson, to participate in featured industry panels and present Company's vision for transforming women's health
Key metrics vs top competitors for Daré Bioscience, Inc. (DARE)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $2.05 | $29.77M | -1.71 | 10429.36% | -1300.66% | -471.37% | — | |
| $4.75 | $192.85M | 3.89 | 36.55% | -19.55% | -3.39% | — | |
| $3.31 | $20.91M | -2.74 | 125.12% | -102.42% | -61.46% | — | |
| $9.30 | $104.91M | 25.14 | 30.75% | 17.66% | 8.33% | — | |
| $85.99 | $1.95B | 25.90 | 43.78% | 9.71% | 17.32% | — | |
| $15.63 | $1.31B | -29.49 | — | — | -38.92% | — |
Daré Bioscience, Inc. (DARE) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Daré Bioscience, Inc. (DARE) SEC filings — annual & quarterly reports (10-K, 10-Q)
May 18, 2026·SEC
May 14, 2026·SEC
May 7, 2026·SEC
Get notified when DARE posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Daré Bioscience, Inc. (DARE) stock FAQ — growth, dividends, profitability & financials explained
Daré Bioscience, Inc. (DARE) reported $1.2M in revenue for fiscal year 2025. This represents a 279% increase from $0.3M in 2011.
Daré Bioscience, Inc. (DARE) grew revenue by 10429.4% over the past year. This is strong growth.
Daré Bioscience, Inc. (DARE) reported a net loss of $12.0M for fiscal year 2025.
Daré Bioscience, Inc. (DARE) has a return on equity (ROE) of -471.4%. Negative ROE indicates the company is unprofitable.
Daré Bioscience, Inc. (DARE) had negative free cash flow of $10.2M in fiscal year 2025, likely due to heavy capital investments.
